Loading...
Pexidartinib: First Approval
Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutati...
Saved in:
| Published in: | Drugs |
|---|---|
| Main Author: | |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer International Publishing
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7044138/ https://ncbi.nlm.nih.gov/pubmed/31602563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01210-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|